Werner Edward Cooper, Chief Financial Officer, on June 02, 2026, sold 2,500 shares in F5 (FFIV) for $1,000,000. Following the Form 4 filing with the SEC, Werner Edward Cooper has control over a total of 406 common shares of the company, with 406 shares held directly.
SEC Filing:
Spencer R Berthelsen, Director, on June 01, 2026, sold 8,000 shares in Ionis Pharmaceuticals (IONS) for $605,360. Following the Form 4 filing with the SEC, Berthelsen has control over a total of 156,083 common shares of the company, with 156,013 shares held directly and 70 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/874015/000087401526000188/xslF345X05/edgardoc.xml
David A Lorber, 10% Owner, Director, Chairman and CEO, on June 01, 2026, executed a purchase for 8,656 shares in Phenixfin (PFX) for $389,605. Following the Form 4 filing with the SEC, Lorber has control over a total of 257,232 common shares of the company, with 253,854 shares held directly and 3,378 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1490349/000121390026064840/xslF345X05/ownership.xml
Saiyed Atiq Raza, Director, on June 01, 2026, sold 70,000 shares in Arteris (AIP) for $2,521,103. Following the Form 4 filing with the SEC, Raza has control over a total of 160,839 common shares of the company, with 20,839 shares held directly and 140,000 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1667011/000118456326000005/xslF345X05/primarydocument.xml